Synthetic antimicrobial β-peptide in dual-treatment with fluconazole or ketoconazole enhances the in vitro inhibition of planktonic and biofilm Candida albicans

Journal of Peptide Science

Volumn 21, Issue 12, 2015, Pages 853-861

  Mora Navarro, Camilo ^a   Caraballo Leõn, Jean ^a   Torres Lugo, Madeline ^a   Ortiz Bermúdez, Patricia ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

biofilm; Candida; candidiasis; checkerboard; combinatorial treatment; fluconazole; HepG2; ketoconazole; synergism; peptides

Indexed keywords

FLUCONAZOLE; KETOCONAZOLE; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CELL DENSITY; CELL PROLIFERATION; CYTOTOXICITY; DRUG COMBINATION; DRUG POTENTIATION; DRUG SCREENING; FRACTIONAL INHIBITORY CONCENTRATION INDEX; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; YEAST CELL; ANTIFUNGAL RESISTANCE; CELL SURVIVAL; DRUG EFFECTS; HEP-G2 CELL LINE; PHYSIOLOGY; PLANKTON;

ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; CANDIDA ALBICANS; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; FLUCONAZOLE; HEP G2 CELLS; HUMANS; IN VITRO TECHNIQUES; KETOCONAZOLE; PLANKTON;

EID: 84955204281     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2827     Document Type: Article

References (39)

1. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman C a, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr K a, Morrison V a, Park BJ, Patterson TF, Perl TM, Oster R a, Schuster MG, Walker R, Walsh TJ, Wannemuehler K a, Chiller TM,. Invasive fungal infections among organ transplant recipients: results of the Transplant-associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 2010; 50: 1101-1111. DOI: 10.1086/651262.
2. Kontoyiannis DP, Marr K a, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt L a, Kauffman C a, Knapp K, Lyon GM, Morrison V a, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler K a, Wingard JR, Chiller TM, Pappas PG,. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-associated Infection Surveillance Network (TRANSNET) database. Clin. Infect. Dis. 2010; 50: 1091-1100. DOI: 10.1086/651263.
3. World Health Organization. Antimicrobial resistance: global report on surveillance 2014, 2014.
4. Pfaller M a,. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 2012; 125: S3-S13. DOI: 10.1016/j.amjmed.2011.11.001.
5. Pierce CG, Srinivasan A, Uppuluri P, Lo L,. In Antibiofilm Agents, Vol. 8, Rumbaugh KP, Ahmad I,. Springer Series on Biofilms. Inhibition of Fungal Biofilms. Springer Berlin Heidelberg: Berlin, Heidelberg, 2014; DOI: 10.1007/978-3-642-53833-9.
6. Maertens JA,. History of the development of azole derivatives. Clin. Microbiol. Infect. 2004; 10 (Suppl 1): 1-10.
7. ® evaluation for synergy with polymyxin B and fluconazole against Candida glabrata. Antimicrob. Agents Chemother. 2014. DOI: 10.1128/AAC.03035-14.
8. Bodey GP,. Azole antifungal agents. Clin. Infect. Dis. 1992; 14: S161-S169. DOI: 10.2307/4456409.
9. Sanglard D, Odds FC,. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2002; 2: 73-85. DOI: 10.1016/S1473-3099(02)00181-0.
10. Marr AK, Gooderham WJ, Hancock RE,. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 2006; 6: 468-472. DOI: 10.1016/j.coph.2006.04.006.
11. Lee M-R, Raman N, Gellman SH, Lynn DM, Palecek SP,. Hydrophobicity and helicity regulate the antifungal activity of 14-helical β-peptides. ACS Chem. Biol. 2014; 9: 1613-1621. DOI: 10.1021/cb500203e.
12. Beke T, Somlai C, Perczel A,. Toward a rational design of β-peptide structures. J. Comput. Chem. 2006; 27: 20-38. DOI: 10.1002/jcc.20299.
13. Seebach D, Matthews JL,. β-Peptides: a surprise at every turn. Chem. Commun. 1997; 1: 2015-2022. DOI: 10.1039/a704933a.
14. Karlsson AJ, Pomerantz WC, Neilsen KJ, Gellman SH, Palecek SP,. Effect of sequence and structural properties on 14-helical β-peptide activity against Candida albicans planktonic cells and biofilms. ACS Chem. Biol. 2009; 4: 567-579. DOI: 10.1021/cb900093r.
15. Murray JK, Gellman SH,. Microwave-assisted parallel synthesis of a 14-helical β-peptide library. J. Comb. Chem. 2006; 8: 58-65. DOI: 10.1021/cc0501099.
16. Karlsson AJ, Pomerantz WC, Weisblum B, Gellman SH, Palecek SP,. Antifungal activity from 14-helical β-peptides. J. Am. Chem. Soc. 2006; 128: 12630-12631. DOI: 10.1021/ja064630y.
17. Cabrele C, Martinek T a, Reiser O, Berlicki Ł,. Peptides containing β-amino acid patterns: challenges and successes in medicinal chemistry. J. Med. Chem. 2014; 57: 9718-9739. DOI: 10.1021/jm5010896.
18. Seebach D, Abele S, Gademann K, Guichard G, Hintermann T, Jaun B, Matthews JL, Schreiber JV,. ' β2- and β3-peptides with proteinaceous side chains : synthesis and solution structures of constitutional isomers, a novel helical secondary structure and the influence of solvation and hydrophobic interactions on folding '. 1998; 81. DOI: 10.1002/hlca.19980810513.
19. Seebach D, Beck AK, Bierbaum DJ,. The world of β- and γ-peptides comprised of homologated proteinogenic amino acids and other components. ChemInform 2005; 36: 1111-1239. DOI: 10.1002/chin.200533334.
20. Kobayashi T, Kakeya H, Miyazaki T, Izumikawa K, Yanagihara K, Ohno H, Yamamoto Y, Tashiro T, Kohno S,. Synergistic antifungal effect of lactoferrin with azole antifungals against Candida albicans and a proposal for a new treatment method for invasive candidiasis. Jpn. J. Infect. Dis. 2011; 64: 292-296.
21. Maurya IK, Thota CK, Sharma J, Tupe SG, Chaudhary P, Singh MK, Thakur IS, Deshpande M, Prasad R, Chauhan VS,. Mechanism of action of novel synthetic dodecapeptides against Candida albicans. Biochim. Biophys. Acta 1830; 2013: 5193-5203. DOI: 10.1016/j.bbagen.2013.07.016.
22. Venkatesh MP, Rong L,. Human recombinant lactoferrin acts synergistically with antimicrobials commonly used in neonatal practice against coagulase-negative staphylococci and Candida albicans causing neonatal sepsis. J. Med. Microbiol. 2008; 57: 1113-1121. DOI: 10.1099/jmm.0.2008/001263-0.
23. Noor F, Niklas J, Müller-Vieira U, Heinzle E,. An integrated approach to improved toxicity prediction for the safety assessment during preclinical drug development using Hep G2 cells. Toxicol. Appl. Pharmacol. 2009; 237: 221-231. DOI: 10.1016/j.taap.2009.03.011.
24. Zhou J, Qi Y, Diao Q, Wu L, Du X, Li Y, Sun L,. Cytotoxicity of melittin and apamin in human hepatic L02 and HepG2 cells in vitro. Toxin Rev. 2013; 32: 60-67. DOI: 10.3109/15569543.2013.852108.
25. McKim JM,. Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance. Comb. Chem. High Throughput Screen. 2010; 13: 188-206.
26. Rodríguez-Tudela JL, Berenguer J, Martínez-Suárez JV, Sanchez R,. Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and flucona. Antimicrob. Agents Chemother. 1996; 40: 1998-2003.
27. Knight SAB, Dancis A,. Reduction of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt (XTT) is dependent on CaFRE10 ferric reductase for Candida albicans grown in unbuffered media. Microbiology 2006; 152: 2301-2308. DOI: 10.1099/mic.0.28843-0.
28. NCCL. Reference method for broth dilution antifungal susceptibility testing of yeast; aproved stadard-third edition, 2008, M27-A3 vol. 8, No 14.
29. Meletiadis J, Mouton JW, Meis JFGM, Verweij PE,. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 2003; 47: 106-117. DOI: 10.1128/AAC.47.1.106-117.2003.
30. Odds FC,. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 2003; 52: 1. DOI: 10.1093/jac/dkg301.
31. Chou T, Martin N,. CompuSyn software for drug combinations and for general dose-effect analysis, and user's guide. Paramus, NJ ComboSyn 2007.
32. Chou TC,. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70: 440-446. DOI: 10.1158/0008-5472.CAN-09-1947.
33. Alvarez-Berríos MP, Castillo A, Mendéz J, Soto O, Rinaldi C, Torres-Lugo M,. Hyperthermic potentiation of cisplatin by magnetic nanoparticle heaters is correlated with an increase in cell membrane fluidity. Int. J. Nanomedicine 2013; 8: 1003-1013. DOI: 10.2147/IJN.S38842.
34. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH,. Combination antifungal therapy. Antimicrob. Agents Chemother. 2004; 48: 693-715. DOI: 10.1128/AAC.48.3.693-715.2004.
35. Lõpez-García B, Gandía M, Muñoz A, Carmona L, Marcos JF,. A genomic approach highlights common and diverse effects and determinants of susceptibility on the yeast saccharomyces cerevisiae exposed to distinct antimicrobial peptides. BMC Microbiol. 2010; 10: 289. DOI: 10.1186/1471-2180-10-289.
36. Lis M, Bhatt S, Schoenly NE, Lee AY, Nislow C, Bobek L a,. Chemical genomic screening of a saccharomyces cerevisiae genome-wide mutant collection reveals genes required for defense against four antimicrobial peptides derived from proteins found in human saliva. Antimicrob. Agents Chemother. 2013; 57: 840-847. DOI: 10.1128/AAC.01439-12.
37. Maruyama M, Matsunaga T, Harada E, Ohmori S,. Comparison of basal gene expression and induction of CYP3As in HepG2 and human fetal liver cells. Biol. Pharm. Bull. 2007; 30: 2091-2097. DOI: 10.1248/bpb.30.2091.
38. Björklund E, Larsson TNL, Jacobsson SOP, Fowler CJ,. Ketoconazole inhibits the cellular uptake of anandamide via inhibition of FAAH at pharmacologically relevant concentrations. PLoS One 2014; 9 e87542:. DOI: 10.1371/journal.pone.0087542.
39. Huang H, Wang H, Sinz M, Zoeckler M, Staudinger J, Redinbo MR, Teotico DG, Locker J, Kalpana GV, Mani S,. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 2007; 26: 258-268. DOI: 10.1038/sj.onc.1209788.